Whole-cell vaccine

Whole-cell vaccines are a type of vaccine that has been prepared in the laboratory from entire cells.[1] Such vaccines simultaneously contain multiple antigens to activate the immune system. They induce antigen-specific T-cell responses.[2]

Whole-cell vaccines have been researched in the fields of bacterial infectious disease (as an inactivated vaccine)[3] and cancer (as tumor cells modified to stimulate the immune system by secreting stimulatory molecules).[2] One whole-cell vaccine that sees global use is the whole-cell pertussis vaccine.[3]

Against infectious disease

Pertussis

The causative organism of pertussis is Bordetella pertussis. The whole-cell pertussis vaccine is effective and safe in treating this disease but is also associated with short-term side effects. Depending upon the different B. pertussis antigens, the immune response produced by the whole-cell vaccine also varies. The pertussis whole-cell vaccine contains inactivated bacterial cells that contain antigens like pertussis toxin, adenylate cyclase toxin, lipooligosaccharides and agglutinogens.[3] The whole-cell pertussis vaccine is prepared by growing Bordetella pertussis in a liquid medium. After the inactivation of the bacteria, a specific cellular concentration is aliquoted. The vaccine efficacy ranges between 36 and 98%.[3]

Advantages over acellular pertussis vaccine
  • Whole-cell pertussis vaccine stimulates natural infection better than the acellular pertussis vaccine.[4][5]
  • Even though cell-mediated immunity persists in patients received with the acellular pertussis vaccine, stronger lymphocytic proliferation, specifically memory T helper 1 cell and T helper 17 cells and cytokine responses are observed in patients received with the whole cell pertussis vaccine.[6][7]
  • The vaccination with whole cell pertussis vaccine ensures the low risks of pulmonary infection and nasal colonization, due to the increased production of Tissue Resident Memory cells.[7][8]

Pneumococcus
See also: Pneumococcal vaccine

The whole-cell pneumococcal vaccine consisted of inactive Streptococcus pneumoniae RM200 cells[9] and was the first whole-cell vaccine used against S. pneumoniae. In 2012, Phase-I studies were conducted by combining the whole-cell vaccine with alum. 1 out of 42 experienced adverse reactions which were not related to vaccination. The mild reactions experienced were similar to the control groups. Immunoglobulin G responses to the whole-cell vaccine was determined by pan proteome microassay and found that the whole-cell pneumococcal vaccine induced an increase in IgG response in a naturally immunogenic protein expressed by RM200 and also caused a reaction to PclA, PspC and ZmpB protein variants.[10]

Against cancer
See also: Cancer vaccine

The whole-cell tumour vaccine is based on the logic that tumour cells will contain proteins produced by cancer lesion and will provide multiple antigens for immune recognition. Whole-cell tumour vaccines represent one form of immunotherapy method undergoing clinical development.[11]

To make a whole-cell tumor vaccine, tumor cells from the patient are transduced so that they produce costimulatory molecules such as cytokines, chemokines, and others. The cells are irradiated so they cannot grow like the parent tumor, but can still express the tumor antigens and the additional molecules.[2]

Phase I & II clinical trials of various whole-cell tumour vaccines indicate this method is safe for cancer patients. The advantage of a whole-cell vaccine is that the cells provide a source of all potential antigens, eliminating the need to identify the most optimal antigen to target in a particular type of cancer. Multiple tumour antigens can be targeted simultaneously, generating an immune response to various tumour antigens.[2]

Advantages
  • Whole tumour cell vaccines contain characterised and uncharacterised Tumour Antigen Associated Cells that can be processed Antigen Presenting Cells to stimulate the immune system; this makes the whole tumour cell vaccine different from other antigen-specific vaccines.[12]
  • Antigen Presenting Cells can present Tumour Associated Antigens to CD8+ and CD4+ T cells via MHC I & II, respectively. The simultaneous presentation of MHC I & II leads to a robust immune response against tumours.[13]
  • Induces immune response to multiple epitopes within an antigenic protein.[14]

Disadvantages
  • The use of whole-tumour cells for vaccine preparation is not very specific because only a portion of the antigens expressed by tumour cells are specific to tumours, and the rest of the antigens are present in normal cells.[15]
  • A tumour biopsy is needed to prepare autologous tumour cell vaccines. In some cases, the cells obtained through tumour biopsy may not be sufficient, or the tumour cells might have undergone necrosis.[16]
  • The Tumour Associated Antigens present in whole tumour cell vaccines can release immunosuppressive cytokines[17] like TGF-β, inhibiting the development of proper immune response.[14]
  • The CD8+ T cell presented by MHC-I does not elicit a response against tumour antigens due to a lack of expression of costimulatory molecules like CD80 & CD86 in these cancer cells.[18]

Mode of action

The whole tumour cell vaccine consists of the identified and unidentified tumour antigens. Antigen-presenting cells present these tumour antigens via Major Histocompatibility Complex Class I & II to CD8+ T lymphocytes and CD4+T lymphocytes, respectively. By interacting with the Fas ligand or secretion of lytic enzymes, cytotoxic T lymphocytes can lead to apoptosis. Active CD4+ T cells activate the Natural-killer cells, and also CD4+T cells activate the humoral immune response and also promote the activity of CD8+ T cells.[19][20] Vaccine-induced immune responses are measured by Delayed type Hypersensitivity responses to autologous tumour cells. The granulocyte-macrophage colony-stimulating factor (GM-CSF) is superior to other cytokines, and the addition of GM-CSF in whole-cell vaccine results in a better response against tumour cells. GM-CSF recruits dendritic cells to the site of irradiated cells and stimulates the antigen uptake, processing and presentation.[21] These dendritic cells facilitate the T-cell response by combining with CD8+ T cells.[22]

See also

References
  1. "Whole cell vaccine". National Cancer Institute. Retrieved 14 October 2022.
  2. Bridget P., keenan; Elizabeth M., Jaffee (2012). "Whole cell vaccines-past progress and future strategies". Seminars in Oncology. 39 (3): 276–286. doi:10.1053/j.seminoncol.2012.02.007. PMC 3356993. PMID 22595050.
  3. Alghounaim, Mohammad; Alsaffar, Zainab; Alfraij, Abdulla; Bin-Hasan, Saadoun; Hussain, Entesar (13 June 2022). "Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy". Medical Principles and Practice. 31 (4): 313–321. doi:10.1159/000525468. PMC 9485965. PMID 35696990.
  4. Higgs, R; Higgins, S; Ross, P; Mills, K (20 June 2012). "Immunity to the respiratory pathogen bordetella pertussis". Mucosal Immunology. 5 (5): 485–500. doi:10.1038/mi.2012.54. PMID 22718262. S2CID 205198195.
  5. Ross, Padraig; Sutton, Caroline; Higgins, Sarah; Allen, Aideen; Walsh, Kevin; Misiak, Alicja; Lavelle, Ed; McLoughlin, Rachel; Mills, Kingston (4 April 2013). "Relative contribution of th1 and th17 cells in adaptive immunity to bordetella pertussis: Towards the rational design of an improved acellular pertussis vaccine". PLOS Pathogens. 9 (4): e1003264. doi:10.1371/journal.ppat.1003264. PMC 3617212. PMID 23592988.
  6. Podda, Audino; Bona, Gianni; Canciani, Gianpaolo; Pistilli, Anna; Contu, Bruno; Furlan, Riccardo; Meloni, Tullio; Stramare, Duilio; Titone, Lucina; Rappuoli, Rino; Granoff, Dan (August 1995). "Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children". The Journal of Pediatrics. 127 (2): 238–243. doi:10.1016/s0022-3476(95)70301-2. PMID 7636648. Retrieved 13 October 2022.
  7. Wilk, Mieszko; Borkner, Lisa; Misiak, Alicja; Curham, Lucy; Allen, Aideen; Mills, Kingston (21 January 2019). "Immunization with whole cell but not acellular pertussis vaccines primes CD4 TRM cells that sustain protective immunity against nasal colonization with Bordetella pertussis". Emerging Microbes & Infections. 8 (1): 169–185. doi:10.1080/22221751.2018.1564630. PMC 6455184. PMID 30866771.
  8. Allen, Aideen C.; Wilk, Mieszko M.; Misiak, Alicja; Borkner, Lisa; Murphy, Dearbhla; Mills, Kingston H. G. (November 2018). "Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells". Mucosal Immunology. 11 (6): 1763–1776. doi:10.1038/s41385-018-0080-x. ISSN 1933-0219. PMID 30127384. S2CID 52053942.
  9. Malley, Richard; Lipsitch, Marc; Stack, Anne; Saladino, Richard; Fleisher, Gary; Pelton, Steven; Thompson, Claudette; Briles, David; Anderson, Porter (2001). "Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci". Infection and Immunity. 69 (8): 4870–4873. doi:10.1128/iai.69.8.4870-4873.2001. PMC 98576. PMID 11447162.
  10. Campo, Joseph; Le, Timothy; Pablo, Jozelyn; Hung, Christopher; Teng, Andy; Tettelin, Herve; Tate, Andrea; Hanage, William; Alderson, Mark; Liang, Xiaowu; Malley, Richard; Lipsitch, Marc; Croucher, Nicholas (28 December 2018). "Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination". eLife. 7: 1–30. doi:10.7554/elife.37015.042. PMC 6344088. PMID 30592459.
  11. Ramirez-Montagut, Teresa (23 January 2015). "Cancer vaccines". Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies: 365–388. doi:10.1016/B978-0-12-416603-5.00015-8. ISBN 9780124166035. Retrieved 30 October 2022.
  12. Petr G, Lokhov; Elena E, Balashova (November 29, 2010). "Cellular Cancer Vaccines: an Update on the Development of Vaccines Generated from Cell Surface Antigens". Journal of Cancer. 1: 230–241. doi:10.7150/jca.1.230. PMC 3001283. PMID 21151581.
  13. Meihua, Chen; Rong, Xiang; Yuan, Wen; Guangchao, Xu; Chunting, Wang; Shuntao, Luo; Tao, Yin; Xiawei, Wei; Bin, Shao; Ning, Liu; Fuchun, Guo; Meng, Li; Shuang, Zhang; Minmin, Li; Kexing, Ren; Yongsheng, Wang; Yuquan, Wei (23 September 2015). "A whole-cell tumour vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumour cells and cancer-associated fibroblasts". Scientific Reports. 5 (1): 39–49. doi:10.1038/srep46841. PMID 14421. S2CID 13490088.
  14. Nancy Diaz, Valdes; Maria, Basagoiti; Javier, Dotor; Fernando, Aranda; Inaki, Monreal; Jose Ignacio, Riezu Boj; Francisco, Borras Cuesta; Pablo, Sarobe; Esperanza, Feijoo (1 February 2011). "Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression". Cancer Research. 71 (3): 812–821. doi:10.1158/0008-5472.CAN-10-2698. PMID 21159663. S2CID 9687255. Retrieved 10 October 2022.
  15. Petr G, Lokhov; Elena E, Balashova (November 29, 2010). "Cellular Cancer Vaccines: an Update on the Development of Vaccines Generated from Cell Surface Antigens". Journal of Cancer. 1: 230–241. doi:10.7150/jca.1.230. PMC 3001283. PMID 21151581.
  16. Yannelli, J (November 2004). "On the road to a tumor cell vaccine: 20 years of cellular immunotherapy". Vaccine. 23 (1): 97–113. doi:10.1016/j.vaccine.2003.12.036. PMID 15519713.
  17. Sheikhi, Abdolkarim; Jafarzadeh, Abdollah; Kokhaei, Parviz; Hojjat-Farsangi, Mohammad (September 2016). "Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15". Iranian Journal of Immunology: IJI. 13 (3): 148–166. ISSN 1735-367X. PMID 27671507.
  18. A A, Cardoso; J L, Schultze; V A, Boussiotis; G J, Freeman; M J, Seamon; S, Laszlo; A, Billet; S E, Sallan; J G, Gribben; L M, Nadler (1 July 1996). "Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen". Blood. 88 (1): 41–48. doi:10.1182/blood.V88.1.41.41. PMID 8704200.
  19. R E, Toes; F, Ossendorp; R, Offringa; C J, Melief (1999). "CD4 T cells and their role in antitumor immune responses". Journal of Experimental Medicine. 189 (1 March 1999): 753–756. doi:10.1084/jem.189.5.753. PMC 2192956. PMID 10049938.
  20. Ronan J, Kelly; Giuseppe, Giaccone (1 September 2012). "Lung Cancer – Vaccines". The Cancer Journal. 17 (5): 302–308. doi:10.1097/PPO.0b013e318233e6b4. PMC 3196521. PMID 21952280.
  21. G, Dranoff; E, Jaffee; A, Lazenby; P, Golumbek; H, Levitsky; K, Brose; V, Jackson; H, Hamada; D, Pardoll; R C, Mulligan (15 April 1993). "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity". Proceedings of the National Academy of Sciences. 90 (8): 3539–3543. Bibcode:1993PNAS...90.3539D. doi:10.1073/pnas.90.8.3539. PMC 46336. PMID 8097319.
  22. Fu, Chunmei; Jiang, Aimin (2018-12-20). "Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment". Frontiers in Immunology. 9: 3059. doi:10.3389/fimmu.2018.03059. ISSN 1664-3224. PMC 6306491. PMID 30619378.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.